Anzeige
Mehr »
Sonntag, 02.11.2025 - Börsentäglich über 12.000 News
Der menschliche Genius hinter den Maschinen: Telescope Innovations und der Aufstieg der autonomen Wissenschaft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
73 Leser
Artikel bewerten:
(0)

United Imaging Healthcare Co., Ltd.: United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the company's revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit, reached CNY 8.86 billion and 1.05 billion, representing a year-over-year increase of 27.39% and 126.94%, respectively.

In Q3 2025, the company achieved revenue of CNY 2.84 billion, up 75.41% year on year, while net profit attributable to ordinary shareholders after deducting non-recurring profit of CNY 0.09 billion.

The company's revenue growth was primarily fueled by the continuous launch of innovative high-end products, now widely recognized in the market, alongside the expansion in overseas markets and the growth of service revenue. In the first three quarters of 2025, overseas revenue reached CNY 1.9 billion, representing a year-over-year increase of 41.97%, accounting for 22.50% of total revenue, respectively.

R&D investment continues to play a pivotal role in driving innovation. In the first three quarters of 2025, United Imaging Healthcare's R&D investment reached CNY 1.86 billion, representing a year-over-year increase of 13.48%. These investments fueled the launch of a series of new products, including uMR Ultra, uMI Panvivo, uAngio AVIVA.

Notably, on September 29, 2025, China's NMPA approved United Imaging's new-generation 3T MRI, uMR Ultra. With FDA clearance and the CE mark already in place, uMR Ultra is officially opening the door to global clinical availability.

As of the date of this report, the company had introduced over 140 innovative products globally, of which 56 were cleared by the U.S. FDA through the 510(k) process and 64 were CE certified under MDR/MDD. United Imaging Healthcare now operates in more than 90 countries and regions.

Looking ahead, United Imaging Healthcare will continue to pursue innovation-driven development, meet global market needs, steadily expand its international presence, serve healthcare systems worldwide, and contribute to the sustainable advancement of human health.

SOURCE United Imaging Healthcare Co., Ltd.

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.